-
Posted by
Two Blokes Jun 10 -
Filed in
Stock
-
8 views
Despite Novo Nordisk's recent stock slide, strong Q1 FY25 results and strategic initiatives reinforce a "Buy" rating, presenting a continued, albeit tested, investment opportunity for patient investors. Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market, despite revised guidance due to compounded drug impacts. NVO actively combats compounded GLP-1s via legal routes, new patient access programs like $499 Wegovy, and key formulary wins such as CVS exclusivity.
